

10/525,985

=> d his

(FILE 'HOME' ENTERED AT 10:20:44 ON 26 MAY 2006)

FILE 'REGISTRY' ENTERED AT 10:21:00 ON 26 MAY 2006

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 10 S L1 FULL


FILE 'CAPLUS' ENTERED AT 10:21:35 ON 26 MAY 2006

L4 12 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

10/525,985

=> d ibib abs hitstr 1-8

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:901908 CAPLUS
DOCUMENT NUMBER: 143:234986
TITLE: Dermo-cosmetic compositions for
depigmentation of skin and their use
INVENTOR(S): Besse, Renand
PATENT ASSIGNEE(S): Laboratoires S.V.R., Fr.
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1566168	A1	20050824	EP 2004-290479	20040223
EP 1566168	B1	20060419		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: EP 2004-290479 20040223


AB A dermo-cosmetic composition having depigmentation action on the skin
comprises the combination of kojic acid esters, diacetylboldine, and
undecenoylphenylalanine. A fluid gel contained dipalmitoyl kojic acid
10.0, dimethicone 1.0, glyceryl tribehenate 0.32, cyclomethicone 3.50,
trihydroxy stearine (Thixogel) 16.0, isononyl isononanoate 25.0,
undecenoyl phenylalanine 5.0, 0.1% diacetylboldine on neutral support
0.05, propylparaben 0.20, methylparaben 0.20, lavandin essence q.s.,
hydrophobic and sphingolipids 0.50 g, and water qs to 100.00 mL.

IT 476-70-0D, Boldine, esters 72584-75-9
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(dermo-cosmetic compns. for depigmentation of skin and their
use)

RN 476-70-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-
methyl-, (6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 72584-75-9 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-
methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/525,985




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:931423 CAPLUS
DOCUMENT NUMBER: 141:400495
TITLE: Skin-lightening cosmetics containing boldines
INVENTOR(S): Odera, Akio; Tanabe, Hiroyuki; Masuda, Junko
PATENT ASSIGNEE(S): Croda Japan K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004307352	A2	20041104	JP 2003-99156	20030402
PRIORITY APPLN. INFO.:			JP 2003-99156	20030402
OTHER SOURCE(S):	MARPAT	141:400495		

GI




I

AB The cosmetics, which show low skin irritation, contain boldines I (n may be 1-8). A cream containing 0.004 weight% I showed good skin color-lightening effect.
IT 73951-75-4
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(skin-lightening cosmetics containing boldines)
RN 73951-75-4 CAPLUS

10/525,985

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:743699 CAPLUS
DOCUMENT NUMBER: 142:341426
TITLE: LUMISKIN: a new mechanism for reducing skin pigmentation
AUTHOR(S): Lintner, Karl
CORPORATE SOURCE: Sederma SAS, UK
SOURCE: Research Disclosure (2004), 480(April), P418-P419 (No. 480011)
CODEN: RSDSBB; ISSN: 0374-4353
PUBLISHER: Kenneth Mason Publications Ltd.
DOCUMENT TYPE: Journal; Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
RD 480011		20040410		

PRIORITY APPLN. INFO.: RD 2004-480011 20040410


AB Enhanced understanding of the process of melanogenesis, and, in particular, the upstream pathways of tyrosinase regulation, have enabled discovery of new active substances called LUMISKIN. The development of LUMISKIN (diacetyl boldine) was based on regulation of tyrosinase activity via two key factors: calcium influx and the stabilization of the inactive form of tyrosinase. The efficacy of LUMISKIN has been demonstrated both in vitro and in vivo studies.

IT 72584-75-9, Lumiskin
RL: BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(efficacy of LUMISKIN (diacetyl boldine) for reducing skin pigmentation)

RN 72584-75-9 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:460358 CAPLUS

DOCUMENT NUMBER: 141:248346

TITLE: Di-acetyl-nor-aporphines: novel molecules and novel mechanism to inhibit melanogenesis

AUTHOR(S): Mas-Chamberlin, C.; Peschard, O.; Leroux, R.; Mondon, Ph.; Lamy, F.; Lintner, K.

CORPORATE SOURCE: Fr.

SOURCE: SOFW Journal (2004), 130(3), 2, 4-8, 10

CODEN: SOFJEE; ISSN: 0942-7694

PUBLISHER: Verlag fuer Chemische Industrie H. Ziolkowsky

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nor-aporphine derivs. have been discovered which interfere with the intra- and extracellular calcium flux. It has been shown that adrenergic antagonists that block the Calcium exchange lead to an inhibition of the phospholipase C/IP3/PKC cascade, thus blocking tyrosinase activation. Di-acetyl-dimethoxy-methyl-nor-aporphine was a semi-synthetic mol. of natural origin with very high potency. On B16 melanocytes as well as in normal human melanocytes the decrease in melanin synthesis reached .apprx.50% at a level of 40 ppm in the culture medium. On a molar concentration

basis, this was 50 to 70 times stronger than Kojic acid inhibition. Yet, the cell viability was not affected. Reversibility studies showed that after washing out of the active compound, melanogenesis returns to normal levels. Possible mechanisms of the activity were discussed. Tests carried out on SkinEthic three-dimensional models of the epidermis and in vivo clin. studies on Asian population confirmed the strong inhibition of melanogenesis. Safety evaluation of these mols., on the other hand, demonstrated good skin tolerance and absence of toxicity.


IT 73951-75-4

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses) (mechanism of skin lightening di-acetyl-nor-aporphines to inhibit melanogenesis)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)

10/525,985



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:181940 CAPLUS

DOCUMENT NUMBER: 140:235926

TITLE: Preparation of new noraporphine derivatives for use in **cosmetic** and dermopharmaceutic compositions

INVENTOR(S): Lintner, Karl

PATENT ASSIGNEE(S): Sederma Sa, Fr.

SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2843963	A1	20040305	FR 2002-10810	20020830
FR 2843963	B1	20041022		
WO 2004024695	A1	20040325	WO 2003-FR2400	20030729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003288304	A1	20040430	AU 2003-288304	20030729
EP 1534682	A1	20050601	EP 2003-780203	20030729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005537332	T2	20051208	JP 2004-535571	20030729
PRIORITY APPLN. INFO.:			FR 2002-10810	A 20020830
			WO 2003-FR2400	W 20030729

OTHER SOURCE(S): MARPAT 140:235926

GI




I

AB The present invention relates to new derivs. I (R1, R2, R3, R4, R5 = H, alkyl, aryl, aralkyl, acyl, sulfonyl sugar) of noraporphine, their optical isomers, their mixts. and their cosmetically acceptable salts, it also relates to all the **cosmetic** and dermopharmaceutic compns. which contain one or more these derivs., only or in partnership with an extract of plant, particularly the *Glaucium flavum*, and in particular the prepsns. having for objective a reduction in the pigmentation, an anti-age effect, or thinning. Thus, 2,9-diacetoxy-1,10-dimethoxy-6-methylnoraporphine [I; R1 = R4 = Ac, R2 = R3 = R5 = Me; Ac = C(=O)Me] was prepared from 2,9-dihydroxy-1,10-dimethoxy-6-methylnoraporphine (I; R1 = R4 = H, R2 = R3 = R5 = Me) via acetylation with Ac2O in CH2Cl2 containing EtN(CHMe2)2. I (R1 = R4 = Ac, R2 = R3 = R5 = Me) was tested for its ability to inhibit lipid peroxidn. [100% @ 0.15 mmol/L] and glycerol-3-phosphate dehydrogenase [76% @ 0.09 mmol/L]. A day cream formulation containing I (R1 = R4 = Ac, R2 = R3 = R5 = Me) is described.

IT 73951-75-4P, 2,9-Diacetoxy-1,10-dimethoxy-6-methylnoraporphine
 RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and bioactivity of new noraporphine derivs. for use in **cosmetic** and dermopharmaceutic compns.)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)




IT 5630-11-5, 1,2,9,10-Tetramethoxy-6-methylnoraporphine
 38849-65-9, 1,2,10-Trimethoxy-9-hydroxy-6-methylnoraporphine
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (preparation and bioactivity of new noraporphine derivs. for use in **cosmetic** and dermopharmaceutic compns.)

RN 5630-11-5 CAPLUS


CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl- (9CI) (CA INDEX NAME)

10/525,985



RN 38849-65-9 CAPLUS

CN 4H-Dibenzo[de,g]quinolin-9-ol, 5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl- (9CI) (CA INDEX NAME)




IT 55056-93-4, 2,9-Dihydroxy-1,10-dimethoxy-6-methylnoraporphine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and bioactivity of new noraporphine derivs. for use in
cosmetic and dermopharmaceutic compns.)

RN 55056-93-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:657924 CAPLUS

DOCUMENT NUMBER: 137:190400


10/525,985

TITLE: Novel **cosmetic** slimming compositions
containing boldine
INVENTOR(S): Lintner, Karl
PATENT ASSIGNEE(S): Sederma, Fr.
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066000	A2	20020829	WO 2002-FR487	20020207
WO 2002066000	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
FR 2820978	A1	20020823	FR 2001-2441	20010221
FR 2820978	B1	20040213		

PRIORITY APPLN. INFO.: FR 2001-2441 A 20010221
AB The invention relates to the use of boldine of any origin (synthesis, vegetable extraction, biotechnol., genetic engineering, etc.), on its own or combined with other active agents, in **cosmetic** or dermatopharmaceutical compns. for the prevention of and/or slimming treatment for excess weight on the thighs and hips, the treatment of cellulite and skin toning.
IT 476-70-0, Boldine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(novel **cosmetic** slimming compns. containing boldine)
RN 476-70-0 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/525,985

INVENTOR(S): Pauly, Gilles; Danloux, Louis; Moser, Phillippe
PATENT ASSIGNEE(S): Laboratoires Serobiologiques, Fr.
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1145709	A1	20011017	EP 2000-440107	20000414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001078675	A1	20011025	WO 2001-EP1171	20010203
W: AU, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001033739	A5	20011030	AU 2001-33739	20010203
EP 1272155	A1	20030108	EP 2001-905732	20010203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003530419	T2	20031014	JP 2001-575977	20010203
US 2003175366	A1	20030918	US 2003-257695	20030313
PRIORITY APPLN. INFO.:			EP 2000-440107	A 20000414
			WO 2001-EP1171	W 20010203


AB The use of natural products, e.g., retinol derivs., retinoic acid, isoflavones, tannins, or plant exts. (Physalis, Stachytarpheta) for the preparation of **cosmetic** compns. is described. Thus, 200 g Physalis min. was extracted with 70-% MeOH and the solvent was removed and the residue was lyophilized. This extract 1.0, Hydagen-CMF 1.0, Emulgade SE 5.0, Cetiol SN 3.0, Cetiol V 3.0, Nutrilan Elastin E-20 2.0, and 86% glycerin 3.0%.

IT 476-70-0, Boldine
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(natural products for **cosmetic** compns.)

RN 476-70-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725428 CAPLUS
DOCUMENT NUMBER: 133:286238

10/525,985

TITLE: **Cosmetic** composition comprising at least one substance promoting the formation of connexins and **cosmetic** treatment method

INVENTOR(S): Nizard, Carine; Provost, Nicolas; Viron, Cecile; Krzych, Valerie; Saunois, Alex

PATENT ASSIGNEE(S): LVMH Recherche, Fr.

SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059466	A1	20001012	WO 2000-FR818	20000331
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2791568	A1	20001006	FR 1999-4165	19990402
FR 2791568	B1	20040402		
EP 1165036	A1	20020102	EP 2000-915266	20000331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002541084	T2	20021203	JP 2000-609030	20000331
PRIORITY APPLN. INFO.:			FR 1999-4165	A 19990402
			WO 2000-FR818	W 20000331

AB The present invention relates to **cosmetic** compns. comprising the following: an active ingredient such as at least one substance that promotes intercellular communication of skin cells, especially keratinocytes, and fibroblasts and pre-adipocytes of the skin; the use of at least one substance promoting intercellular communication of keratinocytes, fibroblasts and pre-adipocytes of the skin as a **cosmetic** agent, optionally in the presence of a cosmetically acceptable vehicle; a method for promoting and/or increasing the activity of a **cosmetic** agent acting directly in the cell or via second intracellular messengers, and a method for treating ageing of the skin using cosmetics. Alc. extract of *Skeletonema costatum* was prepared and its enhancing effects on intercellular communication of cultured skin keratinocytes was studied. Formulation of a cream containing 1% *S. costatum* extract is disclosed.

IT 476-70-0, Boldin


RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(**cosmetic** composition comprising at least one substance promoting formation of connexins and **cosmetic** treatment method)

RN 476-70-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/525,985



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:46:14 ON 26 MAY 2006)

FILE 'REGISTRY' ENTERED AT 11:46:21 ON 26 MAY 2006

L1 STRUCTURE UPLOADED

L2 30 S L1

L3 621 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:46:47 ON 26 MAY 2006

L4 1474 S L3


L5 54321 S COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION?

L6 8 S L4 AND L5

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>